Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6

Documents similaires

• Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b
  par: B. Thompson, et autres
  Publié: (2025)
• Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐CoV‐2 infection
  par: E. Challenger, et autres
  Publié: (2025)
• Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration
  Publié: (2024)
• Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval
  par: N. Neverette, et autres
  Publié: (2025)
• Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19
  Publié: (2024)